Powered by

Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019

Jan 29, 2020 - Thomson Reuters ONE
Mergers and Acquisitions

- Full year net sales for continuing operations1 up 9% (cc2, +6% USD): - Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 million

- Oncology BU growing 10% (cc) driven by Promacta/Revolade USD 1.4 billion (+23% cc), Kisqali USD 0.5 billion (+111% cc) and Lutathera USD 0.4 billion (+160% cc)

- Sandoz sales grew 2% (cc, -1% USD) driven by Biopharmaceuticals

- Core2 operating income grew 17% ...